Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SGN-BB228 |
| Synonyms | |
| Therapy Description |
SGN-BB228 comprises an anti-CD228 antibody linked to anti-calin proteins targeting TNFRSF9 (4-1BB), which potentially leads to enhanced antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SGN-BB228 | SGN BB228|SGNBB228|PRS 346|PRS-346|PRS346 | SGN-BB228 comprises an anti-CD228 antibody linked to anti-calin proteins targeting TNFRSF9 (4-1BB), which potentially leads to enhanced antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05571839 | Phase I | SGN-BB228 | A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors | Active, not recruiting | USA | GBR | FRA | DEU | CHE | CAN | 0 |